TRxADE HEALTH INC
For the period ended Dec 31, 2023. Filed Apr 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 22, 2024
SCNX$3.20+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Years Ended December 31, 2023 and 2022
| Series BPreferred Stock · Series C Preferred Stock · Common Stock · Additional · Non-Controlling · Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · $ Amount · Shares · $ Amount · Shares · $ Amount · Paid-in Capital · Accumulated Deficit · Interest in Subsidiary · Stockholders’ Equity | |||||||||||||
| Balance at December 31, 2021 | - | $ | - | - | $ | - | 544,430 | $5 | $20,017,605 | $(16,247,437) | $ | - | $3,770,173 |
| Capital Contributions | - | - | - | - | - | - | - | - | 792,500 | 792,500 | |||
| Capital Distribution | - | - | - | - | - | - | - | - | (775,000) | (775,000) | |||
| Common stock issued for services | - | - | - | - | 19,511 | - | 254,106 | - | - | 254,106 | |||
| Common stock issued for placement, net issuance costs | - | - | - | 61,334 | 1 | 130,917 | - | - | 130,918 | ||||
| Warrants exercised for cash | - | - | - | - | 972 | - | 875 | - | - | 875 | |||
| Options expense | - | - | - | - | - | - | 79,163 | - | - | 79,163 | |||
| Net loss | - | - | - | - | - | - | - | (3,472,099) | (437,769) | (3,909,868) | |||
| Balance at December 31, 2022 | - | $ | - | - | $ | - | 626,247 | $6 | $20,482,666 | $(19,719,536) | $(420,269) | $342,867 | |
| Common stock issued for services | - | - | - | - | 38,480 | - | 257,772 | - | - | 257,772 | |||
| Warrants exercised for cash | - | - | - | - | 41,911 | 1 | 1,621 | - | - | 1,622 | |||
| Options expense | - | - | - | - | - | - | 29,738 | - | - | 29,738 | |||
| Reverse split rounding adjustment | - | - | - | - | 21,929 | - | - | - | - | - | |||
| Disposition of assets | - | - | - | - | - | - | - | 4,317,170 | 420,269 | 4,737,439 | |||
| Shares issued pursuant to merger agreement | 15,759 | - | - | - | 136,441 | 1 | 12,500,088 | - | - | 12,500,089 | |||
| Shares issued pursuant to securities purchase agreement | - | - | 290 | - | 40,000 | 1 | 516,399 | - | - | 516,400 | |||
| Net loss | - | - | - | - | - | - | - | (17,843,574) | - | (17,843,574) | |||
| Balance at December 31, 2023 | 15,759 | $ | - | 290 | $ | - | 905,008 | $9 | $33,788,284 | $(33,245,940) | $ | - | $542,353 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.